Condition: Glioblastoma · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Glioblastoma Multiforme, Adult · Sponsor: Prof. Franciszek Lukaszczyk Memorial Oncology Center
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma. Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation. The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.
This description comes directly from the study's public registry record.
Agnieszka Rydzewska, Study Coordinator · +48 52 3743082 · glejak@co.bydgoszcz.pl
Always discuss trial participation with your own doctor first.
| Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center | Bydgoszcz, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07668869